On April 7, 2024, NEJM published a paper titled Beta Blockers after Myocardial Infarction and Preserved Ejection Fraction, using β- The clinical practice of receptor blockers provides new references.
picture
Screenshot of NEJM
5020 patients were enrolled in the study, and acute myocardial infarction patients who had undergone coronary angiography and had a left ventricular ejection fraction of ≥ 50% were randomly divided into two groups β- Long term treatment with receptor blockers (metoprolol or bisoprolol) or not accepted β- Receptor blocker therapy.
As a result, it was found that, β- Receptor blocker therapy does not seem to reduce the cumulative incidence of secondary endpoints: β- The all-cause mortality rate of the receptor blocker treatment group was 3.9%, which was not accepted β- The receptor blocker treatment group was 4.1%; The mortality rates from cardiovascular causes were 1.5% and 1.3%, respectively; The myocardial infarction rates were 4.5% and 4.7%, respectively; The hospitalization rates for atrial fibrillation were 1.1% and 1.4%, respectively; The hospitalization rates for heart failure were 0.8% and 0.9%, respectively.
The paper suggests that in patients with acute myocardial infarction who undergo early coronary angiography and retain left ventricular ejection fraction (≥ 50%), long-term β- Receptor blocker therapy and non use β- Compared to receptor blockers, they did not reduce the risk of all-cause death or new onset myocardial infarction. (Information source: NEJM)
